The RadiCaL Study: Testing the Addition of a New Anti-Cancer Drug to the Usual Treatment for Advanced Renal Cell Cancer that has Spread to the Bone

Clinical Trial Title

A031901: A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)

National Clinical Trial Number:

NCT04071223

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have documented histologic or cytologic diagnosis of renal cell cancer (RCC).
  • Have presence of at least 2 metastatic bone lesions not treated with prior radiation.
  • Have no prior therapy with radium-223 dichloride or systemic radiotherapy.
  • Are not pregnant or nursing.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Alan Tan, MD

Contact Information

Rush Cancer Center Clinical Trials Office

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more